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Objectives:  Tumours  can  be categorised  based  on  their  stromal  architecture  into  tumour  vessel  and  stro-
mal vessel  phenotypes,  and the  phenotypes  have  been  suggested  to deﬁne  tumour  response  to  chronic
treatment  with  a VEGFR2  antibody.  However,  it  is  unclear  whether  the  vascular  phenotypes  of  tumours
associate  with  acute  vascular  response  to  VEGFR  tyrosine  kinase  inhibitors  (TKI),  or whether  the  early
changes  in  vascular  function  are  associated  with  subsequent  changes  in tumour  size.  This study  was
sought  to address  these  questions  by  using  xenograft  models  of  human  non-small  cell  lung  cancer  (NSCLC)
representing  stromal  vessel  phenotype  (Calu-3)  and  tumour  vessel  phenotype  (Calu-6),  respectively.
Methods:  For  dynamic  contrast-enhanced  magnetic  resonance  imaging  (DCE-MRI),  nude  mice bearing
established  Calu-3  or Calu-6  xenografts  were  treated  with  a  potent  pan-VEGFR  TKI, cediranib  (6  mg/kg),
at  0  h  and 22 h. DCE-MRI  was  performed  2  h before  the  ﬁrst dose  and  2 h after  the  second dose  of cediranib
to  examine  acute  changes  in  tumour  vessel  perfusion.  Tumours  were  harvested  for  hypoxia  detection
by  CA9  immunohistochemistry.  For  tumour  growth  study,  mice  carrying  established  Calu-3  or  Calu-6
tumours  were  treated  with  cediranib  once  daily  for 5 days.
Results:  Twenty-four  hours  after  cediranib  administration,  the  perfusion  of  Calu-3  tumours  was  markedly
reduced,  with a signiﬁcant  increase  in hypoxia.  In contrast,  neither  perfusion  nor  hypoxia  was  signiﬁcantly
affected  in  Calu-6  tumours.  Tumour  regressions  were  induced  in Calu-3  xenografts,  but not  in  Calu-
6  xenografts,  although  there  was  a trend  towards  tumour  growth  inhibition  after  5 days  of  cediranib
treatment.
Conclusion:  These  ﬁndings  suggest  that tumour  stromal  architecture  may  associate  with acute  tumour
vascular  response  to VEGFR  TKI,  and  this  acute  tumour  vascular  response  may  be a promising  early
predictive  marker  of  response  to  VEGFR  TKI  in  NSCLC.
©  2015  The  Authors.  Published  by  Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the  CC  BY. Introduction
Despite recent advances in cancer treatment, the 5-year
urvival of non-small cell lung cancer (NSCLC) remains low.
ngiogenesis is essential for tumour growth, invasion, and metas-
asis by supplying nutrients and oxygen [1,2], and is correlated
ith poor prognosis of NSCLC [3,4]. Signalling through tyrosine
inase (TK) receptors including vascular endothelial growth factor
VEGF) receptor (VEGFR), platelet-derived growth factor recep-
or (PDGFR), and ﬁbroblast growth factor receptor (FGFR) plays a
∗ Corresponding author.
E-mail address: anderson.ryan@oncology.ox.ac.uk (A.J. Ryan).
ttp://dx.doi.org/10.1016/j.lungcan.2015.08.009
169-5002/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access license  (http://creativecommons.org/licenses/by/4.0/).
critical role in tumour angiogenesis [5], and consequently, inhibit-
ing these receptors has emerged as a compelling approach for
cancer treatment. Indeed, antiangiogenic therapy, particularly anti-
VEGF/VEGFR therapy, has shown promise in treating NSCLC, alone
or in combination with chemotherapy [6–8]. However, despite
some beneﬁts in the clinic, individual responses to anti-angiogenic
agents are variable with many patients failing to beneﬁt. Unfortu-
nately, there are not yet any validated predictive biomarkers for
patient selection for anti-angiogenic therapy.
As anti-angiogenic treatment-induced changes in tumour vas-
cularity occur ahead of the reduction in tumour size, measurement
of functional changes in tumour vessels may  identify early response
to anti-angiogenic treatment. Dynamic contrast-enhanced mag-
netic resonance imaging (DCE-MRI) is a non-invasive imaging
article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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odality that can detect changes in tumour perfusion, and it has
een used to assess anti-vascular therapy response in both preclin-
cal and clinical studies [9–13].
Based on stromal architecture, it has been proposed that human
umours can be categorised into two phenotypes: the tumour ves-
el phenotype in which blood vessels are distributed amongst
umour cells, and the stromal vessel phenotype in which blood
essels are embedded in stroma [14]. Importantly, these two
henotypes appear to deﬁne the tumour response to chronic inhi-
ition of VEGF-signalling using the anti-VEGFR2 antibody, DC101
14]. Compared to anti-VEGFR antibodies, VEGFR tyrosine kinase
nhibitors (TKI) have broader pharmacology proﬁles and may
nhibit additional kinases, thereby causing additional effects on
umour vasculature. However, it is unknown whether these ves-
el phenotypes associate with an acute pharmacodynamic vascular
esponse to VEGFR TKI, or whether the early changes in vas-
ular function associate with later changes in tumour size. To
ddress these questions, we used Calu-3 and Calu-6 human NSCLC
enograft models to represent stromal vessel and tumour ves-
el phenotypes, respectively, and treated tumour-bearing mice
ith cediranib, a highly potent pan-VEGFR TKI with additional
ctivity against c-Kit, PDGFR and FGFR [15]. Cediranib has shown
nti-angiogenic and anti-tumour activity in multiple preclinical
odels of human cancer [15] and in clinical trials [16–18]. Here,
e assessed changes in tumour perfusion and hypoxia after cedi-
anib administration using DCE-MRI and immunohistochemistry,
nd compared the vascular functional changes with tumour growth
nhibition by cediranib.
. Materials and methods
.1. Human NSCLC tumour tissues
Formalin-ﬁxed, parafﬁn embedded NSCLC tumour samples
total n = 38; adenocarcinoma (n = 14), squamous cell carcinoma
n = 24)) were obtained from ProteoGenex, Inc. (Culver City, USA)
ith appropriate ethical approval and with informed consent.
.2. Cell culture
Cell lines were obtained from the American Type Culture Collec-
ion and cultured in advanced DMEM/F12 medium supplemented
ith 5% FBS, 2 mM glutamax, and 50 g/ml penicillin/streptomycin
n a humidiﬁed atmosphere with 7.5% CO2. Cell line identity was
onﬁrmed by sequencing of highly polymorphic loci in the mito-
hondrial DNA [19].
.3. Subcutaneous xenografts
All animal experiments were performed under a licence issued
nder the UK Animals (Scientiﬁc Procedures) Act of 1986. To estab-
ish xenografts, female BALB/C nude mice (6–8 weeks old, Harlan,
olverhampton, UK) were anaesthetised with 2% isoﬂurane and
 × 106 tumour cells in 50% Matrigel (BD Biosciences) were subcu-
aneously injected at a single site on the back of the mouse. Mouse
eights and tumour volumes were measured three times per week
volume = 1/2 × length × width × depth).
.4. Cediranib treatment
When tumours reached approximately 150 mm3, mice were
andomised into two groups. For DCE-MRI study, mice (n = 3/group)
ere dosed with either cediranib (AZD2171, Selleck Chemicals,
ouston, USA) 6 mg/kg or vehicle 1% polysorbate by oral gavage at
 h and 22 h. Tumours were imaged by DCE-MRI 2 h before the ﬁrst 90 (2015) 191–198
treatment and 2 h after the second treatment of cediranib or vehi-
cle. Animals were sacriﬁced immediately after the second DCE-MRI.
For tumour growth study, mice (n = 3/group) were treated with
either cediranib or vehicle 1% polysorbate once daily for 5 days.
Tumour volumes were measured over the course of treatment.
2.5. DCE-MRI
MRI  was  performed in a 4.7T horizontal magnet (Agilent
Technologies, Stockport, UK) using a 25 mm quadrature birdcage
coil. Respiration-gated 3D gradient echo imaging (TE = 0.55 ms,
TR = 1.1 ms,  ﬂip angle 5 degrees) covering a ﬁeld of view of
54 × 27 × 27 mm  at an isotropic resolution of 0.42 mm  was  used for
the DCE. T1 was  quantitatively mapped using variable ﬂip angles
nominally in the range of 0.5–8 degrees with RF transmission ﬁeld
inhomogeneities accounted for [20]. 30 l of 0.5 M contrast agent
gadodiamide (Gd, GE Healthcare) was infused via a tail vein can-
nula, and its uptake was monitored using 100 repetitions of the
respiratory-gated scan.
The DCE-MRI signal was  converted to gadolinium concentra-
tion as described [21]. The tumour region was manually segmented
from an average image of the DCE-MRI time course using ITK-SNAP
[22]. The initial area under the gadolinium uptake curve (IAUC) was
calculated for the ﬁrst 90 s on a voxel by voxel basis using in-house
software written in Matlab as previously described [23], and the
median for the tumour was  determined [24].
2.6. Immunohistochemistry
Sections (4 m)  from parafﬁn-embedded tumours from
xenografts or NSCLC tumour samples were deparafﬁnised fol-
lowed by heat-induced epitope retrieval in citrate buffer (pH6.0).
Sections were stained for CA9 (carbonic anhydrase 9) or CD31
using Dako EnVisionTM - Dual link system-HRP (Dako) according to
the manufacturer’s instructions. The antibodies used for immuno-
histochemistry were: CA9 (mouse M75  monoclonal, AB1001,
BioScience, 1:800) and CD31 (rabbit polyclonal, ab28364, Abcam,
1:50). Hematoxylin and eosin (H&E) and Masson’s trichrome
staining were performed for routine histological examination.
Human NSCLC tumours were scored for stromal vessel and tumour
vessel phenotypes based on CD31 and Masson’s trichrome stains.
The presence of intravascular erythrocytes identiﬁed functional
vessels. Tumours showing strong predominance (≥90%) of func-
tional vessels within desmoplastic stroma or within tumour tissue
were deﬁned as either stromal vessel or tumour vessel pheno-
types, respectively. Where functional vessels consisted of >10%
of each phenotype, the tumours were scored as a mixed vessel
phenotype. Similarly, 12 NSCLC xenografts (PC9, H1975, H2087,
H1395, COR-L105, A549, HCC827, Calu-6, Calu-3, H460, H3122,
H1299) and an additional 31 xenografts or allografts from other
types of tumours (HL-60, KARPAS-299, MOLM-13, MV4-11, C6,
SK-N-MC, Colo-205, HCT-116, HT29, LoVo, LS-174T, RKO, SW620,
MKN-1, MKN-45, Alexander, AsPC1, Mia-Paca2, RENCA, A375,
A431, B16-F10, LNCaP, PC-3, MCF7, MDA-MB-231, C33A, HeLa,
OVCAR-3, SKOV-3, NCI-H69) were assessed for vessel phenotypes.
2.7. Statistical analysisData were expressed as mean ± SEM. Statistical analysis was
performed using Student’s t-test by SPSS software. Statistical sig-
niﬁcance was  deﬁned as P < 0.05.
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. Results
.1. NSCLC xenografts and patient samples display distinct
umour vessel and stromal vessel phenotypes
Calu-3 and Calu-6 xenografts were stained for the endothelial
ell marker CD31. Consistent with the previous report [14], Calu-3
umours displayed the stromal vessel phenotype where the vessels
re exclusively embedded within extensive desmoplastic stroma,
hich surrounded the tumour cells (Fig. 1A). In contrast, Calu-6
umours showed exclusively a tumour vessel phenotype where
essels are distributed within the tumour tissue (Fig. 1B).
To investigate the relevance of the vessel phenotypes in human
SCLC, tumour samples were stained for CD31 (Fig. 1C) and with
asson’s trichrome (Fig. 1D). The mean (±SEM) area of tumour
ections evaluated was 1.26 ± 0.08 cm2 and functional vessels were
dentiﬁed by the presence of intravascular erythrocytes. Among the
uman NSCLC tumour samples (n = 38), 19 exhibited a stromal ves-
el phenotype and 18 exhibited a mixed vessel phenotype, with
nly one sample showing exclusively a tumour vessel phenotype
Fig. 1E). Tumours with a mixed vessel phenotype were hetero-
eneous, with areas with vessels embedded in stroma adjacent to
reas with vessels surrounded by tumour cells (Fig. 1C and D). The
istribution between the vessel phenotypes was similar for both
denocarcinoma and squamous cell carcinoma (Fig. 1E). In con-
rast, only 2/12 of NSCLC xenograft models (HCC827, Calu-3) and
/31 of other xenograft models (MKN-1) showed a stromal vessel
henotype with overall, the great majority of xenografts (40/43)
howing a tumour vessel phenotype, and none showing a mixed
essel phenotype (Fig. 1F).
.2. Gadolinium uptake in Calu-3 xenografts is decreased
ollowing acute cediranib treatment
DCE-MRI measures both perfusion and permeability. Thus, to
valuate the impact of cediranib on tumour vascular function,
nimals bearing Calu-3 or Calu-6 xenografts were treated with
ediranib or vehicle twice, 22 h apart. DCE-MRI was  performed 2 h
efore the ﬁrst dose and 2 h after the second dose. The time points
hosen for DCE-MRI were based on the fact that cediranib has a
alf-life of 22 h [25], and reaches its maximum effect at 2 h in mice
fter a single oral dosing [26]. The median IAUC was  calculated
or the tumour in each animal. The average baseline IAUC of Calu-
 tumours was signiﬁcantly higher than that of Calu-6 tumours
P < 0.01) (Fig. 2A), suggesting that Calu-3 tumours were better-
erfused than Calu-6 tumours. The median IAUC in Calu-3 tumours
as reduced by 55.85 ± 4.06% after cediranib administration (pre-
s post-cediranib: P < 0.001), whereas IAUC in Calu-3 tumours was
ot signiﬁcantly affected by vehicle treatment (P = 0.727) (Fig. 2B).
n contrast, the median IAUC of Calu-6 tumours was not sig-
iﬁcantly changed by vehicle or cediranib treatment (pre- vs
ost-vehicle: P = 0.857; pre- vs post-cediranib: P = 0.803) (Fig. 2C).
alu-3 tumours at baseline displayed uniform and high perfusion,
ut gadolinium uptake was sharply reduced after cediranib treat-
ent (Fig. 2D). Calu-6 tumours at baseline showed a well-perfused
im with a poorly perfused central region, which was  unchanged
fter cediranib treatment (Fig. 2D). Taken together, these data sug-
est that Calu-3 tumour vessels are more sensitive to cediranib
reatment.
To relate changes in IAUC to histopathology, the extent of
ecrosis was assessed by H&E staining (Fig. 2E). Necrosis was not
vident in vehicle-treated Calu-3 tumours, but cediranib treat-
ent resulted in widespread acellular regions throughout the
umours, consistent with the hypointense regions seen in Calu-3
CE-MRI images. In contrast, a necrotic core was  evident in both
ehicle- and cediranib-treated Calu-6 tumours, corresponding to 90 (2015) 191–198 193
the hypointense central region seen in Calu-6 DCE-MRI images.
There was no evident difference in necrotic fraction between
vehicle-treated and cediranib-treated Calu-6 tumours.
3.3. Acute hypoxia is induced in Calu-3 tumours following
cediranib
To investigate whether the tumour perfusion change resulted in
oxygenation changes, tumour hypoxia was  assessed by immuno-
histochemical staining for the endogenous hypoxia marker CA9
[27], in Calu-3 and Calu-6 tumours harvested 2 h after the second
dose of cediranib or vehicle treatment. CA9 positive staining was
rare in vehicle-treated Calu-3 tumours (Fig. 3A and B), suggesting
that Calu-3 tumours are well-oxygenated, whereas cediranib-
treated Calu-3 tumours showed signiﬁcantly higher hypoxic
fractions compared to the vehicle-treated control (P < 0.001; Fig. 3A
and B), suggesting that cediranib treatment induced acute hypoxia,
consistent with reduced perfusion. In comparison, CA9 staining in
Calu-6 tumours was  evident in perinecrotic areas of the tumours
(Fig. 3A) and hypoxic fractions in cediranib- and vehicle-treated
animals were similar (14.8 ± 2.6% vs 12.1 ± 0.9%; P = 0.382; Fig. 3C),
suggesting no signiﬁcant effect of cediranib on Calu-6 tumour oxy-
genation.
3.4. Reduction in tumour perfusion associates with tumour
growth inhibition
To evaluate whether the early reduction in tumour perfusion
was associated with tumour growth inhibition, mice bearing Calu-
3 and Calu-6 tumours were treated with cediranib once daily for 5
days, and tumour volumes were measured and plotted. Regression
of Calu-3 tumours was evident as early as 2 days after the onset
of cediranib treatment, and persisted throughout the whole treat-
ment course. Statistically signiﬁcant growth inhibition by cediranib
in Calu-3 tumours was obtained on day 4 post-treatment, and
continued till the experiment’s end on day 5. (P < 0.01) (Fig. 4A).
However, no shrinkage of Calu-6 tumours was  observed. Although
there was a trend for cediranib to inhibit Calu-6 tumour growth
after 5 days cediranib treatment (Fig. 4B), it did not reach statistical
signiﬁcance (P = 0.07).
4. Discussion
It has been suggested that the vascular phenotypes of tumours
categorised by stromal architecture can deﬁne tumour response to
chronic VEGF-targeted monotherapy [14]. However, the impact of
this phenotypic variability on acute tumour vascular response to
VEGFR TKI treatment has not been reported. To extend the pre-
vious study [14], we investigated the acute vascular response to
cediranib in two  NSCLC xenograft models representing tumour
vessel and stromal vessel phenotypes, respectively, and compared
the acute vascular responses with tumour growth inhibition. We
found that the perfusion of Calu-3 tumours (stromal vessel pheno-
type) was  rapidly reduced after cediranib administration, leading
to acute hypoxia (within 24 h). In comparison, neither the perfu-
sion nor hypoxia was signiﬁcantly affected by cediranib in Calu-6
tumours (tumour vessel phenotype). Moreover, tumour regression
was induced in Calu-3 xenografts, but not in Calu-6 xenografts after
5 days of cediranib treatment, although there was  a trend towards
tumour growth inhibition in Calu-6 xenografts. Taken together, our
results suggest that tumour stromal architecture may  be associated
with acute tumour vascular response to VEGFR TKI.Previous gene expression analysis has shown that the two
vascular phenotypes of tumours exhibit differential gene expres-
sion proﬁles [14]. Compared with the tumour vessel phenotype,
tumours with stromal vessels express higher levels of certain
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Fig. 1. Distinct vessel phenotypes in NSCLC xenografts and human tumour samples. (A) CD31 immunohistochemistry staining in Calu-3 tumours. (B) CD31 immunohis-
tochemistry staining in Calu-6 tumours. (C) CD31 immunohistochemistry staining in human NSCLC tumours showing a mixed vessel phenotype. (D) Masson’s trichrome
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gtaining in human NSCLC tumours showing a mixed vessel phenotype. (E) Proportio
n  xenografts of NSCLC and other cancers grown in nude mice. Phenotypes were sc
he  presence of intravascular erythrocytes. Arrows and arrow heads indicate vessel
enes associated with recruitment of stromal cells, most notably
DGF and FGF [14]. In addition, vasculature of the tumour ves-
el phenotype tends to be pericyte-free, whereas vasculature of
he stromal vessel phenotype is pericyte covered [14]. Vascula-
ure with pericyte coverage is less sensitive to VEGF inhibition,
ut anti-VEGF/VEGFR therapy may  be improved by concomitant
nhibition of PDGFR expressed on pericytes [28]. Hence, cediranib
reatment by inhibiting pan-VEGFR, PDGFR, and FGFR may  have a
reater effect on tumours with a stromal vessel phenotype than vessel phenotypes in human NSCLC tumours. (F) Proportions of vessel phenotypes
from CD31 and Masson’s trichrome staining. Functional vessels were identiﬁed by
stroma respectively. Scale bars = 100 m.
treatment with a highly selective VEGFR2-signalling inhibitor such
as DC101.
Acute vascular response is characteristic of vascular disrupting
agents (VDAs) [29]. Our data here suggest that cediranib may  be act-
ing, at least in part, as a VDA on the stromal vasculature in Calu-3
xenografts. However, the VEGFR2 blocking antibody, DC101 did not
show signiﬁcant effect in the Calu-3 xenograft model [14], suggest-
ing inhibition of other VEGF receptors, PDGFR and FGFR signalling
may be required to acutely disrupt vessel function in this model.
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Fig. 2. Acute vascular response to cediranib treatment in NSCLC xenografts. Mice bearing Calu-3 or Calu-6 tumours were treated with cediranib (6 mg/kg) or vehicle at 0 h
and  22 h. DCE-MRI imaging was  performed 2 h before the ﬁrst and 2 h after the second treatment. (A) DCE-MRI analysis of basal tumour perfusion. Calu-3 tumours show
signiﬁcantly higher gadolinium uptake compared to Calu-6 tumours. **P < 0.01 (B) The average IAUC values of Calu-3 xenografts pre- and post-treatment. Compared to
the  baseline, gadolinium uptake was signiﬁcantly reduced in Calu-3 tumours by cediranib treatment. ***P < 0.001 (C) The average IAUC values of Calu-6 xenografts pre- and
post-treatment. Compared to the baseline, gadolinium uptake was  not affected by cediranib in Calu-6 tumours. (D) Representative MRI  images from single slides of Calu-3 and
Calu-6 tumours pre- and post-cediranib treatment. (E) Tumour H&E histological staining in vehicle- or cediranib- treated Calu-3 and Calu-6 tumours. Acellular regions were
widespread in cediranib-treated Calu-3 tumours, but were rare in vehicle-treated Calu-3 tumours. No difference in necrotic fraction between vehicle- and cediranib-treated
Calu-6 tumours was  noted. Scale bars = 100 m.
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Fig. 3. Immunohistochemical detection of tumour hypoxia. Tumour-bearing mice treated with two  doses of cediranib or vehicle were sacriﬁced after DCE-MRI. Tumours
were  sectioned and hypoxia was  identiﬁed by CA9 immunohistochemistry. (A) CA9 staining in vehicle or cediranib treated Calu-3 and Calu-6 tumours. Vehicle-treated Calu-3
tumours showed rare CA9 staining, whereas cediranib-treated Calu-3 tumours showed extensive CA9 positive areas. Calu-6 tumours showed similar levels of peri-necrotic
staining of CA9 in both vehicle- and cediranib-treated animals. Scale bars = 100 m. (B) Hypoxic fractions in Calu-3 tumours treated with vehicle or cediranib. ***P < 0.001.
(C)  Hypoxic fractions in Calu-6 tumours treated with vehicle or cediranib.
Fig. 4. Effects of cediranib on tumour growth in Calu-3 and Calu-6 xenograft models. Calu-3 or Calu-6 tumour-bearing mice were treated with either cediranib or vehicle
by  oral gavage once daily for 5 days. Tumour volumes were measured and growth curves were plotted. (A) Calu-3 tumour growth curves. Cediranib treated Calu-3 tumours
showed a signiﬁcantly smaller tumour size and tumour regression compared to vehicle-treated controls. **P < 0.01. (B) Calu-6 tumour growth curves. Cediranib treated Calu-6
tumours showed a trend towards growth inhibition, but this did not reach statistical signiﬁcance. ns: not signiﬁcant.
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In contrast, no signiﬁcant effect of acute cediranib treatment
as detected in Calu-6 tumours by using DCE-MRI. It has previ-
usly been reported that cediranib-induced vessel pruning was
nly apparent in the periphery of the Calu-6 tumours [26]. Since
essel pruning occurs preferentially in immature or non-functional
lood vessels [30], the overall impact of cediranib treatment on
stablished functional tumour vasculature may  be limited in Calu-
 xenografts and therefore could not be detected by DCE-MRI. In
nother DCE-MRI study [31], cediranib treatment reduced Ktrans,
 biomarker of tumour perfusion and vessel permeability, after
 or 5 days of treatment in Calu-6 xenografts, suggesting that
ore prolonged treatment with cediranib can produce signiﬁcant
nti-vascular effects. Nonetheless, in agreement with our study,
o tumour growth inhibition was observed over 5 days of cedi-
anib treatment. This is consistent with other ﬁndings whereby
igniﬁcant tumour growth inhibition was only evident in Calu-6
enografts after 2 weeks of DC101 treatment [14]. These results
uggest that the response of Calu-6 xenografts to cediranib treat-
ent is characteristic of VEGF signalling inhibition in human
umour xenografts, whereby more prolonged treatment is required
32], which is associated with changes in vessel permeability,
ncreased vascular normalisation [33] and inhibition of new blood
essel development [34].
Although xenograft models in NSCLC and other cancers exhibit
istinct vessel phenotypes, human NSCLC tumours are histologi-
ally heterogeneous as shown in our study: a high proportion of
umours having a mixed vessel phenotype, with both tumour ves-
el and stromal vessel phenotypes present within the same tumour.
n addition, in our analysis, only 1/38 human NSCLC tumour sam-
les had a predominantly tumour vessel phenotype compared with
0/12 NSCLC xenograft models. This suggests that the tumour vas-
ulature in xenograft models is not a good representation of the
linical situation. Therefore, deﬁning patient subgroups by tumour
tromal architecture can be difﬁcult in the clinic, especially where
nly small biopsies are available.
Of interest, Calu-3 tumours were better and more uniformly per-
used throughout the tumour than the Calu-6 xenografts which
ere well-perfused only at the tumour rim, suggesting that
CE-MRI may  provide a potential non-invasive biomarker to dis-
riminate stromal and tumour vessel phenotypes. It has been
eported that acute changes in tumour vessel function are more
redictive of tumour growth response than changes in histol-
gy or gene proﬁles [35]. Moreover, quantitative DCE-MRI has be
sed in breast cancer xenografts as an early predictor of response
o bevacizumab treatment [36] and neoadjuvant chemotherapy
37,38]. Comparable to those ﬁndings, our study showed that
educed tumour perfusion following cediranib was  associated with
nhanced tumour growth inhibition, indicating that acute reduc-
ion in tumour perfusion could be an early predictive marker of
esponse to vascular targeted therapies in NSCLC. Indeed, some
vidence suggests that reduction in tumour perfusion associates
ith better response to VEGF-inhibitor therapy in lung cancer.
fter bevacizumab treatment, NSCLC patients with more than
0% reduction in tumour perfusion had a longer progression-free
urvival [39]. Another clinical study on NSCLC patients treated
ith anti-angiogenic chemotherapy also showed that tumour
ascular volume was reduced signiﬁcantly in responders versus
on-responders [40]. In addition, decreased tumour blood volume
uring antiangiogenic therapy was associated with a clinic beneﬁt
n lung cancer patients [41].
It is noteworthy that reduced perfusion can lead to acute
ypoxia as shown in Calu-3 tumours. Increased hypoxia might
ecrease the efﬁcacy of cytotoxic therapies when anti-VEGF/VEGFR
reatment is combined with radiotherapy or chemotherapy. How-
ver, some studies have shown that even in the case of tumour
ypoxia induced by antiangiogenic therapy, the antitumour effects
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can still be enhanced by combined chemotherapy [42,43]. The
underlying mechanism might be independent of hypoxia. Future
studies are warranted to explore the effects of cediranib in combi-
nation with chemo- or radiotherapy in lung cancer.
In this study, acute vascular response to cediranib was evaluated
in two  NSCLC xenograft models. Future studies are warranted to
evaluate a broad range of xenograft models in lung cancer and other
tumour types. Furthermore, it will be of interest to determine the
correlation between the acute vascular response to VEGFR TKI and
the long-term outcome in NSCLC patients.
In conclusion, we  propose that tumour stromal architecture may
affect the response of tumour vasculature to VEGFR TKI treatment,
and that acute change in tumour perfusion may  be predictive of
tumour response to VEGFR TKI in NSCLC.
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